Is there a Bearish outlook for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) this week?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Logo
Investors sentiment decreased to 1.13 in 2019 Q2. Its down 0.30, from 1.43 in 2019Q1. It fall, as 44 investors sold Sarepta Therapeutics, Inc. shares while 84 reduced holdings. 50 funds opened positions while 95 raised stakes. 68.70 million shares or 7.49% less from 74.26 million shares in 2019Q1 were reported.
Stanley stated it has 2,168 shares or 0.08% of all its holdings. Vanguard owns 0.04% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 6.23 million shares. Jpmorgan Chase & reported 97,860 shares or 0% of all its holdings. Budros Ruhlin & Roe, a Ohio-based fund reported 7,400 shares. Dynamic Cap Management holds 3.54% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 4,677 shares. State Street, a Massachusetts-based fund reported 1.36M shares. Proshare Advsrs Ltd Company holds 0.02% or 23,354 shares in its portfolio. Quantitative Systematic Strategies Ltd Liability Company has invested 0.08% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). M&T State Bank Corporation has invested 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Sumitomo Mitsui Hldg reported 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Janney Montgomery Scott Limited Liability owns 4,078 shares. Aqr Cap Ltd Limited Liability Company stated it has 16,420 shares or 0% of all its holdings. Botty Ltd, a Illinois-based fund reported 24,234 shares. Shine Invest Advisory Services holds 0% or 32 shares. Atika Cap Ltd Liability Co holds 92,000 shares or 2.75% of its portfolio.

Since August 12, 2019, it had 4 insider buys, and 0 selling transactions for $2.55 million activity. Another trade for 16,252 shares valued at $2.00M was bought by INGRAM DOUGLAS S. Another trade for 2,000 shares valued at $173,480 was bought by BONNEY MICHAEL W. Another trade for 1,300 shares valued at $159,250 was bought by Barry Richard.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 10 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sarepta Therapeutics has $267 highest and $16500 lowest target. $199’s average target is 129.90% above currents $86.56 stock price. Sarepta Therapeutics had 18 analyst reports since March 25, 2019 according to SRatingsIntel. The firm has “Outperform” rating given on Tuesday, August 20 by Robert W. Baird. The stock has “Buy” rating by Citigroup on Tuesday, March 26. Bank of America maintained the stock with “Buy” rating in Tuesday, August 20 report. The company was maintained on Monday, March 25 by Cantor Fitzgerald. As per Tuesday, June 25, the company rating was maintained by Cantor Fitzgerald. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Buy” rating by Piper Jaffray on Friday, June 21. Credit Suisse maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Tuesday, August 20. Credit Suisse has “Outperform” rating and $20100 target. The stock has “Buy” rating by H.C. Wainwright on Monday, March 25. As per Monday, March 25, the company rating was maintained by Needham. On Tuesday, August 20 the stock rating was maintained by Janney Capital with “Buy”. Below is a list of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) latest ratings and price target changes.

20/08/2019 Broker: Robert W. Baird Rating: Outperform Old Target: $202.0000 New Target: $181.0000 Maintain
20/08/2019 Broker: Bank of America Rating: Buy Old Target: $200.0000 New Target: $189.0000 Maintain
20/08/2019 Broker: Credit Suisse Rating: Outperform Old Target: $207.0000 New Target: $201.0000 Maintain
20/08/2019 Broker: Janney Capital Rating: Buy Old Target: $200.0000 New Target: $175.0000 Maintain
09/07/2019 Broker: Inc. – Common Stock Rating: Morgan Stanley New Target: $165.0000 220.0000
01/07/2019 Broker: Inc. – Common Stock Rating: Rbc Capital New Target: $188.0000 220.0000
25/06/2019 Broker: Cantor Fitzgerald Rating: Buy New Target: $231 Maintain
21/06/2019 Broker: Piper Jaffray Rating: Buy New Target: $208 Maintain
16/05/2019 Broker: Inc. – Common Stock Rating: Citigroup New Target: $201.0000 190.0000
09/05/2019 Broker: Inc. – Common Stock Rating: Rbc Capital New Target: $191.0000 188.0000

The stock decreased 1.61% or $1.42 during the last trading session, reaching $86.56. About 718,414 shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 29.09% since September 13, 2018 and is uptrending. It has outperformed by 29.09% the S&P500.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $6.44 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Nasdaq.com which released: “Noteworthy Tuesday Option Activity: SRPT, RTRX, PG – Nasdaq” on April 23, 2019, also Nasdaq.com with their article: “Company News For Aug 21, 2019 – Nasdaq” published on August 21, 2019, Finance.Yahoo.com published: “Weekly CEO Buys Highlight – Yahoo Finance” on August 18, 2019. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Seekingalpha.com and their article: “After The Dust Has Settled, Key Sarepta Therapeutics Insiders Are Still Buying Shares And So Should Investors – Seeking Alpha” published on August 30, 2019 as well as Finance.Yahoo.com‘s news article titled: “The Sarepta Therapeutics (NASDAQ:SRPT) Share Price Is Up 612% And Shareholders Are Delighted – Yahoo Finance” with publication date: June 18, 2019.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.